KPI data tables

GSK operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

GSK Arexvy Sales by Region (Quarterly) (GBP millions)
PeriodUSEuropeInternational
Q3 20265510337
Q2 2026653097
Q1 202618434
Q4 20257110621
Q3 20251407536
Q2 2025351813
Q1 202555194

Source: GSK plc quarterly results announcements, Vaccines turnover tables, RSV / Arexvy row by region (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm US 55 / Europe 103 / International 37, total 195. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf US 65 / Europe 30 / International 97, total 192. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 18 / 43 / 4, total 65. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 71 / 106 / 21, total 198. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 140 / 75 / 36, total 251. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 35 / 18 / 13, total 66. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 55 / 19 / 4, total 78. FY 2023 1,238 / FY 2024 590 / FY 2025 593 from the 2025 Annual Report on Form 20-F three-year Vaccines turnover table https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf.

GSK HIV Franchise Sales (Quarterly) (GBP millions)
PeriodDovatoCabenuvaApretudeOther HIV
Q3 2026754478143741
Q2 2026749453140736
Q1 2026666368120670
Q4 2025758410129852
Q3 2025695357120772
Q2 2025655341101783
Q1 202557029489761

Source: GSK plc quarterly results announcements, Specialty Medicines turnover tables, HIV product rows (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm Dovato 754 / Cabenuva 478 / Apretude 143 / HIV total 2,116. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf Dovato 749 / Cabenuva 453 / Apretude 140 / HIV total 2,078. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 666 / 368 / 120 / 1,824. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 758 / 410 / 129 / 2,149. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 695 / 357 / 120 / 1,944. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 655 / 341 / 101 / 1,880. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 570 / 294 / 89 / 1,714. Other HIV is HIV total minus the three named products. FY 2025 Dovato 2,678 / Cabenuva 1,402 / Apretude 439 / HIV 7,687 in the 2025 Annual Report on Form 20-F https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf.

GSK Shingrix Sales by Region (Quarterly) (GBP millions)
PeriodUSEuropeInternational
Q3 2026290289201
Q2 2026245434209
Q1 2026389461176
Q4 2025331370307
Q3 2025256297277
Q2 2025241359253
Q1 2025372291204

Source: GSK plc quarterly results announcements, Vaccines turnover tables, Shingles / Shingrix row by region (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm US 290 / Europe 289 / International 201, total 780. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf US 245 / Europe 434 / International 209, total 888. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 389 / 461 / 176, total 1,026. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 331 / 370 / 307, total 1,008. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 256 / 297 / 277, total 830. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 241 / 359 / 253, total 853. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 372 / 291 / 204, total 867. FY 2025 US 1,200 / Europe 1,317 / International 1,041 in the 2025 Annual Report on Form 20-F investor information https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf.

GSK Turnover by Product Group (Quarterly) (GBP millions)
PeriodSpecialty MedicinesVaccinesGeneral Medicines
Q3 20263,8772,5832,427
Q2 20263,7822,2842,343
Q1 20263,2262,1492,254
Q4 20253,8052,2932,520
Q3 20253,4092,6782,460
Q2 20253,3272,0912,568
Q1 20252,9332,0952,488

Source: GSK plc quarterly results announcements, turnover by product group table (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm Q3 2026 Specialty 3,877 / Vaccines 2,583 / General Medicines 2,427. Q2 2026 (28 Jul 2026) https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf Q2 2026 Specialty 3,782 / Vaccines 2,284 / General Medicines 2,343. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 3,226 / 2,149 / 2,254. FY 2025 / Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf Q4 3,805 / 2,293 / 2,520. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 3,409 / 2,678 / 2,460. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 3,327 / 2,091 / 2,568. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 2,933 / 2,095 / 2,488. Three-year annual totals in the 2025 Annual Report on Form 20-F investor information https://www.gsk.com/media/0t2lqb2w/2025-annual-report-on-form-20-f.pdf and https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf (Specialty 13,474 / Vaccines 9,157 / General Medicines 10,036 in 2025).

GSK Vaccines Turnover by Product (Quarterly) (GBP millions)
PeriodShingrixMeningitisArexvyInfluenzaEstablished / other paediatric and adult
Q3 2026780599195177832
Q2 202688846219211731
Q1 20261,0263356510713
Q4 20251,00831319880694
Q3 2025830541251216840
Q2 2025853379666787
Q1 2025867350781799

Source: GSK plc quarterly results announcements, Vaccines turnover tables (amounts in millions of pounds). Q3 2026 (28 Oct 2026, Form 6-K) https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm Shingles 780 / Meningitis 599 / RSV 195 / Influenza 177 / Other Paediatric and Adult Vaccines 832, Vaccines 2,583. Q2 2026 https://www.gsk.com/media/jayh41pz/q2-2026-results-announcement.pdf Shingles 888 / Meningitis 462 / RSV 192 / Influenza 11 / Other Paediatric and Adult Vaccines 731, Vaccines 2,284. Q1 2026 https://www.gsk.com/media/hpgfxwxv/q1-2026-results-announcement.pdf 1,026 / 335 / 65 / 10 / 713, Vaccines 2,149. Q4 2025 https://www.gsk.com/media/g0lnid23/fy-2025-results-announcement.pdf 1,008 / 313 / 198 / 80 / Established 694, Vaccines 2,293. Q3 2025 https://www.gsk.com/media/snycbnpn/q3-2025-results-announcement.pdf 830 / 541 / 251 / 216 / 840, Vaccines 2,678. Q2 2025 https://www.gsk.com/media/zhfdbsly/q2-2025-results-announcement.pdf 853 / 379 / 66 / 6 / 787, Vaccines 2,091. Q1 2025 https://www.gsk.com/media/lwfjtr0d/q1-2025-results-announcement.pdf 867 / 350 / 78 / 1 / 799, Vaccines 2,095. FY 2025 mix in the 2025 Annual Report on Form 20-F https://www.gsk.com/media/3rxjw5di/investor-information-2025.pdf Shingles 3,558 / Meningitis 1,583 / RSV 593 / Influenza 303 / Established 3,120, Vaccines 9,157.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
GSK (GSK) - KPIs | Sterling